The MEND Trial: OptiMized REsistaNt Starch in Inflammatory Bowel Disease

PI: Dr. David Mack

Study contact: [email protected]

Study contact full name: Ruth Singleton

Research Area: Inflammatory Bowel Disease

Who to contact regarding participation: [email protected]

Lay Summary: 

Participants are invited to join in this trial because you are currently enrolled in the main microbiome study and have already been diagnosed with IBD, either Crohn’s Disease (CD) or ulcerative colitis (UC).

This study is being done to find out if the use of RS that is optimized for each individual will help alter and/or restore the “healthier” microbiome of the gut. It does not change the IBD treatment your doctor will use to treat your CD or UC. To do this, some of the participants in this study will get RS and others will receive a placebo (a substance that looks like the study RS but does not have any active or medicinal ingredients). The placebo in this study is not intended to have any effect on your IBD. A placebo is used to make the results of the study more reliable.